Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events Meeting Abstract

  

Authors:	Shoushtari, A. N.; Postow, M. A.; Horvat, T. Z.; Adel, N. G.; Dang, T.; Chapman, P. B.
Abstract Title:	Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events
Meeting Title:	51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	33
Issue:	15 Suppl.
Meeting Dates:	2015 May 29-Jun 2
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2015-05-20
Language:	English
ACCESSION:	WOS:000358036904046
PROVIDER:	wos
DOI:	10.1200/JCO.2015.33.15_suppl.e20023
Notes:	Meeting Abstract: e20023 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/80591